A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial
Latest Information Update: 06 Aug 2026
At a glance
- Drugs Retatrutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms TRIUMPH-2
- Sponsors Eli Lilly and Company
Most Recent Events
- 30 Jul 2026 Status changed from active, no longer recruiting to completed.
- 23 Jul 2026 Primary endpoint has been met. (Percent Change from Baseline in Body Weight)
- 23 Jul 2026 Topline Results presented at Eli Lilly and Company media release.